Contact
Country websites

Conference Call on Q2 2026 financial results

The Conference Call on Q2 2026 took place on August 4, 2026

Learn more

VBC Expert Call

Gain insights into our Value-Based Care business from Tommy O’Connor, President, Value-Based Care.

Learn more
Investor Presentation

Investor Presentation

Our current presentation for investors including strategy, financial data and outlook

Learn more
204040-GlenBurnie, Glen Burnie, Maryland - November 22: Fresenius Kidney Care on November 22, 2024 (Photo by Ferran Traite Soler/Getty Images for Fresenius Medical Care

Sustainability

Managing sustainability successfully means creating lasting value – economically, ecologically and socially.

Learn more
FAQ

FAQ

Answers to the most important questions.

Learn more
Meeting_room

Q2 2026
financial results

VBC Expert Call

Investor Presentation

Investor Presentation

Sustainability

Sustainability

FAQ

FAQ

Helen Giza
Fresenius Medical Care delivered another quarter of highly profitable growth, driven by solid organic revenue growth and improved profitability. Care Delivery achieved strong operating income growth. Importantly, underlying operating income improved by 34% excluding the positive TDAPA effects, driven by rate improvements and benefits from revenue cycle management. The U.S. rollout of our innovative 5008X CAREsystem is progressing at speed, now available in 227 U.S. clinics, having performed more than 600,000 treatments. We are excited by the benefits we are seeing through early insights from our scientific research initiative BEACON-US and the potential for this therapy to significantly improve patient outcomes in the U.S. Operating income growth in the first half was in line with our planned phasing for the full year and we confirm our outlook for 2026. Through disciplined execution of the FME Reignite strategy, we are further improving the quality of patient care, investing in innovation and profitable future growth, addressing regulatory headwinds – creating long-term value for our shareholders.

Helen Giza

Chief Executive Officer

Latest Documents

Links

Replay

Analyst Presentation

PDF

pdf

Investor Presentation

PDF, 6 MB

10/20/2026 - 11/02/2026 | Reporting

Q3 2026 Quiet Period

Save the date

11/03/2026 | Reporting

Report on 3rd quarter 2026: Earnings Release and Conference Call

Save the date

11/06/2026 | Reporting

Q3 financial report

Save the date

01/26/2027 - 02/22/2027 | Reporting

Q4/FY 2026 Quiet Period

Save the date

08/26/2026 | Roadshow

IR Roadshow

Stockholm

Save the date

09/01/2026 | Conference

Commerzbank / ODDO BHF Corporate Conference

Frankfurt

Save the date

09/01/2026 - 09/02/2026 | Roadshow

IR Roadshow

San Diego

Save the date

09/01/2026 | Roadshow

IR Roadshow

Los Angeles

Save the date

You are interested in our news?

Order our news

Would you like to be included on our distribution list for our news? We would be happy to provide you with our latest press releases and short news by e-mail. This service is free of charge and may be cancelled at any time.

You can cancel this free service at any time by sending an e-mail to
ir(at)freseniusmedicalcare.com, or by calling +49 (0) 6172 609 2525.

The information you provide will only be used to answer your query. For more information on how we process your Personal Data please read our 
privacy policy.

Media center
See all stories
No Results Found
See all stories
PREVIOUS
    NEXT
    Events
    See all events
    No Results Found
    See all events
    PREVIOUS
      NEXT
      Contact
      Country websites

      All contact information

      Social Media

      © Fresenius Medical Care AG 2026

      Privacy policy

      Cookie settings

      Imprint